Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung

Keyphrases

• Well-differentiated 100%
• Lung Neuroendocrine Tumors 100%
• Typical Carcinoid 66%
• Atypical Carcinoid 66%
• Everolimus 50%
• Neuroendocrine Tumor 33%
• Early Treatment 16%
• Malignancy 16%
• Placebo 16%
• Lung 16%
• Patient Demographics 16%
• Disease Progression 16%
• Systemic Therapy 16%
• Chemotherapy 16%
• Tumor Subtype 16%
• Large Population 16%
• Natural History 16%
• Disease Risk 16%
• Clinical Evidence 16%
• Guideline Recommendations 16%
• Gastrointestinal Tract 16%
• Risk Reduction 16%
• Timely Diagnosis 16%
• Successful Treatment 16%
• Accurate Diagnosis 16%
• Increased Incidence 16%
• Heterogeneous Groups 16%
• Controlled Experiment 16%
• Enhanced Awareness 16%
• Non-specificity 16%
• Prompt Diagnosis 16%
• Site of Origin 16%
• Multidisciplinary Approach 16%
• Inconsistency 16%
• Assessment Treatment 16%
• Lack of Consensus 16%
• Resectable Disease 16%
• Standardized Treatment 16%
• Evidence-based Care 16%
• Neuroendocrine Cells 16%
• Advanced Wells 16%
• RAD001 16%
• RADIANT-4 16%
• Advanced Neuroendocrine Tumors 16%
• Therapeutic Evidence 16%

Medicine and Dentistry

• Neuroendocrine Tumor 100%
• Carcinoid 88%
• Everolimus 44%
• Awareness 22%
• Disease 11%
• Symptom 11%
• Disease Exacerbation 11%
• Cancer 11%
• Patient Population 11%
• Placebo 11%
• Controlled Clinical Trial 11%
• Systemic Therapy 11%